Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy

Source: MDLinx, November 2019

A total of 103 individuals with immunotherapy for metastatic melanoma were randomly distributed into training (n?=?69) and validation cohort (n?=?34) in order to recognize predictive clinical and CT imaging biomarkers and evaluate their predictive capability about overall survival (OS) and treatment response in individuals with metastatic melanoma who were undergoing immunotherapy. Independent predictors of OS were baseline S100B, tumor burden and Kurtosis and these were verified in the validation cohort. Tumor burden and Kurtosis explicated incremental predictive capability providing a good predictive model when combined with baseline S100B levels. Just S100B was auspicious of treatment response. Nonetheless, treatment response was not prognosticated by imaging biomarkers. Hence, in individuals with metastatic melanoma undergoing immunotherapy, readily achievable baseline clinical (S100B) and CT predictors (tumor burden and Kurtosis) of OS were recognized. Notwithstanding, treatment response was not prognosticated by imaging predictors.